
How Ajinomoto Thailand and MUFG Are Pioneering Well-Being Through Food and Finance
On January 28 in Bangkok, experts from two very different industries — food and finance — came together to explore the theme of well-being .
Japan 2 Earth sat down with Ichiro Sakakura, President of Ajinomoto Thailand Co, Ltd and Ajinomoto SEA Regional Headquarters Co, Ltd, whose company plays a central role in promoting Thai food culture.
Joining him was Yuji Kosugi, then Head of the Chemicals & Well-Being Division at MUFG Bank — a department dedicated to tackling social challenges through financial solutions. Their discussion centered on ESG (Environmental, Social, and Governance) initiatives.
Excerpts follow.
Sakakura (Ajinomoto): We've shifted from fossil fuels to biomass and introduced biomass cogeneration using rice husks at our factories. Also, we've nearly achieved zero GHG emissions from our direct and indirect operations. Now, we're working on reducing emissions across the entire supply chain. In terms of packaging, we've transitioned 56% of all product packaging to recyclable materials. Sakakura passionately speaks about Ajinomoto's vision. (©JAPAN Forward by Mika Sugiura)
Sakakura (Ajinomoto): In Thailand, sugar is often used to deepen flavor and richness, not just to add sweetness. For example, at noodle shops, after choosing the noodles and soup, people often add vinegar, sugar, chili, and fish sauce, which can lead to excessive sugar and salt intake.
Food culture varies by region, so standardization is difficult. However, ANPS categorizes Thai cuisine into 10 types and assigns scores. This year [2025], we hope to scientifically validate it in collaboration with Mahidol University, which has a strong reputation in nutrition. Nutrition education from a young age is also key. It's still at the idea stage, but we hope to introduce ANPS in schools in the future. Dishes classified into 10 categories using ANPS. (Courtesy of Ajinomoto)
Kosugi (MUFG): I've heard that Ajinomoto developed ANPS as a contribution to society. The next important step is certification. We're actively involved in food rule-making, and we'd like to support these efforts by leveraging our neutral position as a financial institution. Kosugi speaks about "rule-making" for food. (©JAPAN Forward by Mika Sugiura)
Sakakura: Ajinomoto uses 20% of the 1 million tons of tapioca starch distributed domestically in Thailand, making us the largest starch user. Cassava farmers are therefore essential. However, climate change and the spread of cassava mosaic virus are reducing yields.
To ensure a stable supply, we launched the "Thai Farmer Better Life Partner Project" in 2020. We hold workshops on plant diseases and use soil analysis to help prevent infections. The number of participating farms has grown from 180 to 1,500. I'm happy to report that their harvests have improved.
We're also building a green resource cycle. We provide low-cost fertilizer made from amino acid-rich by-products of our production process. Additionally, we reuse rice husk ash from biomass power generation as a soil conditioner. Our next step is to establish traceability so that harvests from participating farmers can be directly used in our factories. Cassava farmers participating in the program. (Courtesy of Ajinomoto)
Sakakura: Well-being is a broad concept, so we've been discussing internally what it means for Ajinomoto. It goes beyond the environment and includes three pillars: Customer, Employee, and Society. It represents our commitment to sustainability-centered management.
MUFG Bank has renamed one of its divisions to include the word "well-being." Isn't this quite rare?
Kosugi: Our thinking aligns closely with Ajinomoto's. Looking ten years ahead, we envisioned what our division should become. So, in October last year [2024], we renamed the "Sales Division 5" to the "Chemicals & Well-Being Division." I believe it's the only one of its kind in the world.
Sakakura: We hold a 90% market share in umami seasonings in Thailand and have built three top brands, thanks to our predecessors. We also maintain a nationwide distribution network and stable operations across our seven factories.
One of our key strengths is that all factory managers are Thai and deeply rooted in their communities. A major challenge, however, is the declining population — similar to Japan. In response, we're developing products for an aging society, such as amino acid-based supplements to help prevent muscle loss. Sakakura and Kosugi connecting over shared ideas. (©JAPAN Forward by Mika Sugiura)
Sakakura: When I worked in human resources in Japan, I met Masami Atarashi, the former president of Johnson & Johnson, who was a guest lecturer. I've always liked his phrase "Kotsu-Kotsu-Katsu-Kotsu" [steady effort leads to steady success] — a reminder to keep pushing forward without giving up.
For more than 60 years, Ajinomoto Thailand has quietly and steadily focused on the work at hand, consistently delivering results. That mindset remains unchanged.
This report is published in cooperation with Ajinomoto, a logo partner of the JAPAN Forward website Japan 2 Earth focused on initiatives to achieve the SDGs. It was first published on Japan 2 Earth .
Author: Mika Sugiura
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
14 hours ago
- Globe and Mail
Wet Age-Related Macular Degeneration (Wet-AMD) Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight
Wet Age-Related Macular Degeneration Companies are Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. (Albany, USA) DelveInsight's ' Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Wet Age-Related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet Age-Related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration market. Key Takeaways from the Wet Age-Related Macular Degeneration Market Report In May 2025, Kodiak Sciences Inc announced results of a Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In May 2025, NexThera Co., Ltd announced results of a Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD) In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023. The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future. Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases). Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM. Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023. The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023. Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases). Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM. In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand). The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR. The leading Wet Age-Related Macular Degeneration Companies such as Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Marketed Drugs • BEOVU (Brolucizumab): Novartis BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules. • EYLEA (aflibercept): Regeneron Pharmaceuticals EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials. • VABYSMO (faricimab): Roche/ Genentech, Inc. VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels. Wet Age-Related Macular Degeneration Emerging Drugs • OPT-302: Opthea Limited OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. • KSI-501: Kodiak Sciences Inc. KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. Wet Age-Related Macular Degeneration Market Outlook Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients. The Wet Age-Related Macular Degeneration (wAMD) market is driven by several key factors, including the rising prevalence of the disease due to an aging global population, increased awareness and early diagnosis, and ongoing advancements in treatment options such as anti-VEGF therapies and emerging gene therapies. Additionally, robust research pipelines, growing healthcare expenditure, and supportive government initiatives further contribute to market growth. However, the market also faces notable barriers, such as the high cost of treatment, limited accessibility in low-income regions, the need for frequent intravitreal injections, and challenges in achieving long-term efficacy and patient adherence. Moreover, competition among therapeutic alternatives and the complex nature of drug development for retinal diseases can also hinder market expansion. Wet Age-Related Macular Degeneration Drugs Uptake The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration. Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols – BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others Scope of the Wet Age-Related Macular Degeneration Market Report Coverage- 7MM Study Period- 2020-2034 Wet Age-Related Macular Degeneration Companies- Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals Table of Content 1 Key Insights 2 Report Introduction 3 Wet AMD Market Overview at a Glance 4 Wet AMD Market: Future Perspective 5 Executive Summary 6 Key Events 7 Disease Background and Overview 8 Epidemiology and Patient Population 9 Patient Journey 10 Marketed Drugs 11 Emerging Drugs of Wet AMD 12 Wet AMD: Market Analysis 13 Key Opinion Leaders' Views 14 SWOT Analysis 15 Unmet Needs 16 Market Access and Reimbursement 17 Appendix 18 DelveInsight Capabilities 19 Disclaimer About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:

CBC
15 hours ago
- CBC
Japanese lunar lander crashes during attempted touchdown
Social Sharing A private lunar lander from Japan crashed while attempting a touchdown Friday, the latest casualty in the commercial rush to the moon. The Tokyo-based company ispace declared the mission a failure several hours after communication was lost with the lander. Flight controllers scrambled to regain contact, but were met with only silence and said they were concluding the mission. Communications ceased less than two minutes before the spacecraft's scheduled landing on the moon with a mini-rover. Until then, the descent from lunar orbit seemed to be going well. CEO and founder Takeshi Hakamada apologized to everyone who contributed to the mission, the second lunar strikeout for ispace. Two years ago, the company's first moonshot also ended in a crash landing, giving rise to the name "Resilience" for its successor lander. "This is the second time that we were not able to land. So we really have to take it very seriously," Hakamada told reporters. He stressed that the company would press ahead with more lunar missions. Possible problem with laser system Preliminary analysis indicates the laser system for measuring the altitude did not work as planned, and the lander descended too fast, officials said. "Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface," the company said in a written statement. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience was targeting the top of the moon, a less treacherous place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris, or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Engineers 'did everything' possible Plans had called for the 2.3-metre Resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fibre-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just five kilograms, was going to stick close to the lander, going in circles at a speed of less than a few centimetres per second. It was capable of venturing up to one kilometre from the lander. Minutes before the attempted landing, Hakamada assured everyone that ispace had learned from its first failed mission. "Engineers did everything they possibly could" to ensure success this time, he said. He considered the latest moonshot "merely a steppingstone" to its bigger lander launching by 2027 with NASA involvement. Ispace, like other businesses, does not have "infinite funds" and cannot afford repeated failures, Jeremy Fix, chief engineer for the company's U.S. subsidiary, said at a conference last month. While not divulging the cost of this latest mission, company officials said it's less than the first one which exceeded $100 million US. Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos's Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030.


Globe and Mail
20 hours ago
- Globe and Mail
Collagen & Gelatin Market worth US$1,671.3 million in 2030 5.8% CAGR
"The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel)" Browse 280 market data Tables and 53 Figures spread through 252 Pages and in-depth TOC on "Collagen & Gelatin Market by Source (Bovine, Porcine, Marine), Application (Orthopedic, Cardiovascular, Dental, Surgical), Competitive Landscape (Company Profile, Market share, Company Evaluation Matrix), End User, and Region - Global Forecast to 2030 The global Collagen & Gelatin Market, valued at US$1,203.9 million in 2024, is forecasted to grow at a robust CAGR of 5.8%, reaching US$1,295.5 million in 2025 and an impressive US$1,671.3 million by 2030. Growing incidence of diabetes, cancer, and chronic diseases; rising demand for advanced wound care products; surge in surgical procedures; increasing use in tissue engineering and regenerative medicine; extensive application of collagen as a drug delivery system are driving the market. Browse in-depth TOC on " Collagen & Gelatin Market" 228 - Tables 44 - Figures 240 - Pages By Based on segment, the collagen & gelatin market is divided into bovine, porcine, and others. The large share of the bovine segment can be attributed to the growing adoption of bovine-derived collagen and gelatin in regenerative medicine. Additionally, the increased usage of biomaterials is primarily due to the biocompatibility and biodegradability properties exhibited by these materials. By Based on application, The collagen market is segmented into orthopaedic, wound care, dental, surgical, cardiovascular, and other applications. In 2024, the orthopaedic application segment accounted for the largest share of the collagen market by applications due to the rising demand for scaffolds and substitutes due to their extensive use in orthopaedic surgeries. This dominance is expected to continue throughout the forecast period due to the rising number of road trauma cases. By geography, the collagen & gelatin market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America held the largest share of the collagen & gelatin market, followed by Europe. Asia Pacific registered the highest CAGR growth within the collagen & gelatin market during the forecast period due to its increasing application for research and clinical diagnostics, adoption of collagen & gelatin for transplantation-associated research, and government initiatives and industrial collaboration. The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel), Collagen Solutions plc (UK), Regenity (US), Medtronic plc (Ireland), and Solventum (US). INTEGRA LIFESCIENCES (US): Integra LifeSciences leads in the collagen & gelatin market. It operates through two business segments, namely Codman Specialty Surgical and Tissue Technologies. The company offers engineered bovine collagen, bovine dermis, porcine urinary bladder, human amniotic tissue, and resorbable synthetic mesh products through its Tissue Technologies Segment. This segment recorded a decline of 3.3% in 2024 over 2023 due to the impact of the lost revenue related to the Boston product recall, which was partially offset by double-digit growth from BioD and Gentrix and mid-single-digit growth in Integra skin and MediHoney. The company's leading position is attributable to its diversified product portfolio, geographical expansion, and adoption of organic and inorganic growth strategies. For instance, in March 2024, Integra Life Sciences received an US FDA approval to commercialize a dermal regeneration template for repairing scar contractures. SMITH+NEPHEW PLC (UK): Smith+Nephew is one of the leading players in the collagen & gelatin market due to its robust portfolio, including innovative collagen-based scaffolds and collagenase-based enzymatic debridement agents. The company operates through three business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers collagen and gelatin products through its advanced wound management business segment. Additionally, the company's strong global presence, strategic partnerships, and commitment to customer-centric solutions position it as a key player in the competitive collagen and gelatin space. The company possesses a strong geographical presence with a broad range of distribution networks to solidify its leadership in the collagen and gelatin market. The advanced wound management business segment of Smith+Nephew has experienced a positive growth rate of 4.7% in the year 2024 and maintained positive momentum in 2024, with growth accelerating toward the end of the year. For more information, Inquire Now!